Mechanism
HER2 (JSKN003 ADC component) + PD-L1 (envafolimab component)
Assets acting on this target.
- Class
- fixed-dose combination of a HER2-targeted antibody-drug conjugate and a PD-L1 immune checkpoint inhibitor
- Pathway
- HER2-directed cytotoxic payload delivery combined with PD-L1 checkpoint blockade